Mitchell Clough

Mintz

+ Follow Contact

Latest Posts › Inflation Reduction Act (IRA)

Share:

Appeals Court Rejects AstraZeneca’s Challenge to Medicare Drug Price Negotiation Program

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug Negotiation Program...more

5/13/2025 / Administrative Procedure Act , Appeals , Centers for Medicare & Medicaid Services (CMS) , Constitutional Challenges , Drug Pricing , Inflation Reduction Act (IRA) , Judicial Review , Medicare , Pharmaceutical Industry , Prescription Drugs

Mintz IRA Update — Fourth Edition: Q1 2025

Mintz’s Pharmacy Benefits and PBM Contracting Practice is pleased to present the ‘Fourth Edition: Q1 2025’ of our Mintz IRA Update, a regular publication that delves into developments of the Inflation Reduction Act of 2022...more

2/14/2025 / Drug Pricing , Inflation Reduction Act (IRA) , Medicare , Medicare Part D , Pharmaceutical Industry , Pharmacy Benefit Manager (PBM) , Prescription Drugs , Regulatory Agenda , Regulatory Requirements , Supply Chain

Mintz IRA Update — IRA Litigation Update: Courts Begin to Address Legal Challenges to the Medicare Drug Price Negotiation Program

The IRA’s Medicare Drug Price Negotiation Program (the “Negotiation Program” or “Program”), which enables the federal government to negotiate prices for some of the costliest Medicare Part D drugs, has been subject to several...more

7/16/2024 / AstraZeneca , Centers for Medicare & Medicaid Services (CMS) , Constitutional Challenges , Dismissals , Drug Pricing , Fifth Amendment , Inflation Reduction Act (IRA) , Infringement , Medicare , Negotiations

3 Results

View per page

Page: of 1